Exelixis anticipates approval of new drug zanzalinib and Q3 revenue growth
EXEL Exelixis Inc
$68.50 +2.09%
View chart & analysis → - 1Exelixis recorded a 10% year-over-year revenue growth rate in Q3.
- 2Exelixis achieved $658.7 million in revenue for Q3.
- 3The US Food and Drug Administration extended the review period for zanzalinib.
So what's the key point?
Exelixis revenue increased by 10 percent compared to last year in the third quarter. It remains to be seen how the company's growth will proceed as the review for new drug approval is delayed.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.